Imprimis Pharmaceuticals Inc (IMMY) 7.91 $IMMY
Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 11:28PM CDT
IMMY: 7.91 (-0.09)
Imprimis reports 4Q loss
Automated Insights - Thu Mar 12, 3:58PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $2.7 million in its fourth quarter.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:20PM CDT
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results and Provides Business Update
PR Newswire - Thu Mar 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 7.91 (-0.09)
Nasdaq stocks posting largest volume decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
INTG: 19.41 (+0.06), SIBC: 20.87 (+0.01), PPSI: 9.00 (unch), UBOH: 15.14 (-0.03), GRIF: 31.25 (-0.78), USBI: 8.28 (-0.02), HTWO: 9.70 (-0.11), MCBK: 20.50 (-1.21), EVAR: 4.10 (+0.09), HWBK: 13.80 (+0.93), SCYX: 9.25 (-0.48), SBFG: 10.92 (+0.36), GCBC: 28.00 (-0.50), TLF: 8.45 (-0.12), IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops(TM) Combination Eye Drop Formulations Following LASIK Surgery
PR Newswire - Tue Feb 03, 6:30AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and Cleveland Eye Clinic, today announced positive results of an investigator-initiated evaluation validating the use of Imprimis' proprietary combination topical formulations for patients post-LASIK surgery. Imprimis plans to begin fulfilling prescription orders for LessDrops(TM) formulations by the end of February 2015.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Announces Two Key Leadership Promotions
PR Newswire - Mon Feb 02, 3:01PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced that it has promoted John Saharek to Chief Commercial Officer and Andrew R. Boll to Chief Financial Officer. Mr. Saharek will be responsible for leading the company's commercial activities, including formulation portfolio management, market access, sales and marketing and customer service. Mr. Boll will continue to oversee accounting and financial reporting, investor relations, human resources and other operational departments.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings
PR Newswire - Tue Jan 13, 6:30AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced it will be exhibiting at two upcoming ophthalmology meetings: the Fourth Annual Cataract Surgery: Telling It Like It Is! meeting from January 15 - 18 in Sarasota, FL (Booth #33), and the Hawaiian Eye and Retina 2015 meeting from January 17 - 23 in Maui, HI (Booth #111).
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops(TM)
PR Newswire - Thu Jan 08, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced its plans to introduce proprietary triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and prednisolone acetate and moxifloxacin hydrochloride (Pred-Moxi) combination eye drop formulations for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK) surgery, cataract and other ocular surgeries.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Appoints Dr. Richard L. Lindstrom to its Board of Directors
PR Newswire - Mon Jan 05, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced the appointment of internationally-renowned ophthalmologist, Richard L. Lindstrom, M.D., to the company's Board of Directors.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States
PR Newswire - Wed Dec 03, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four key states: California, Nevada, Oregon, and Hawaii. These states represent over 290 ambulatory surgery centers (ASCs) where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country.
IMMY: 7.91 (-0.09)
Imprimis acquires second pharmacy
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:43AM CST
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California
PR Newswire - Tue Dec 02, 7:05AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a stock purchase agreement to acquire South Coast Specialty Compounding, Inc., DBA Park Compounding (Park). The acquisition of Park is expected to close on or about January 1, 2015, subject to the satisfaction of certain customary closing conditions. As part of the transaction, Imprimis also entered into a non-exclusive license agreement with Park. The license agreement allows Park to immediately begin making and dispensing Imprimis' proprietary ophthalmology and urology formulations in the 13 states in which it is currently licensed, including California, Nevada, Oregon, and Hawaii.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals EPS of -$0.27
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:26PM CST
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments
PR Newswire - Wed Nov 12, 3:00PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced financial results for the third quarter ended September 30, 2014, and provided an update on recent business developments.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014
PR Newswire - Thu Nov 06, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, reported that it will release its third quarter 2014 financial results on Wednesday, November 12, 2014. The company will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day to discuss the third quarter 2014 financial results and recent business development activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless(TM) Proprietary Formulations to Ophthalmologists in Puerto Rico
PR Newswire - Tue Nov 04, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a distribution agreement with MD Distributor, Corp. (MDD). Under the agreement, MDD has the rights to market, sell and distribute Imprimis' patent-pending Go Dropless(TM) formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement also covers the Dominican Republic and countries in the Caribbean once regulatory approvals are obtained. MDD represents leading healthcare companies and its experienced sales and marketing professionals are primarily focused in the specialty areas of ophthalmology and dermatology.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation
PR Newswire - Wed Oct 29, 7:31AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
PR Newswire - Fri Oct 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois. The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible".
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 11:28PM CDT
IMMY: 7.91 (-0.09)
Imprimis reports 4Q loss
Automated Insights - Thu Mar 12, 3:58PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $2.7 million in its fourth quarter.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:20PM CDT
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results and Provides Business Update
PR Newswire - Thu Mar 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 7.91 (-0.09)
Nasdaq stocks posting largest volume decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
INTG: 19.41 (+0.06), SIBC: 20.87 (+0.01), PPSI: 9.00 (unch), UBOH: 15.14 (-0.03), GRIF: 31.25 (-0.78), USBI: 8.28 (-0.02), HTWO: 9.70 (-0.11), MCBK: 20.50 (-1.21), EVAR: 4.10 (+0.09), HWBK: 13.80 (+0.93), SCYX: 9.25 (-0.48), SBFG: 10.92 (+0.36), GCBC: 28.00 (-0.50), TLF: 8.45 (-0.12), IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops(TM) Combination Eye Drop Formulations Following LASIK Surgery
PR Newswire - Tue Feb 03, 6:30AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and Cleveland Eye Clinic, today announced positive results of an investigator-initiated evaluation validating the use of Imprimis' proprietary combination topical formulations for patients post-LASIK surgery. Imprimis plans to begin fulfilling prescription orders for LessDrops(TM) formulations by the end of February 2015.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Announces Two Key Leadership Promotions
PR Newswire - Mon Feb 02, 3:01PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced that it has promoted John Saharek to Chief Commercial Officer and Andrew R. Boll to Chief Financial Officer. Mr. Saharek will be responsible for leading the company's commercial activities, including formulation portfolio management, market access, sales and marketing and customer service. Mr. Boll will continue to oversee accounting and financial reporting, investor relations, human resources and other operational departments.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings
PR Newswire - Tue Jan 13, 6:30AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced it will be exhibiting at two upcoming ophthalmology meetings: the Fourth Annual Cataract Surgery: Telling It Like It Is! meeting from January 15 - 18 in Sarasota, FL (Booth #33), and the Hawaiian Eye and Retina 2015 meeting from January 17 - 23 in Maui, HI (Booth #111).
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops(TM)
PR Newswire - Thu Jan 08, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced its plans to introduce proprietary triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and prednisolone acetate and moxifloxacin hydrochloride (Pred-Moxi) combination eye drop formulations for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK) surgery, cataract and other ocular surgeries.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Appoints Dr. Richard L. Lindstrom to its Board of Directors
PR Newswire - Mon Jan 05, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced the appointment of internationally-renowned ophthalmologist, Richard L. Lindstrom, M.D., to the company's Board of Directors.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States
PR Newswire - Wed Dec 03, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four key states: California, Nevada, Oregon, and Hawaii. These states represent over 290 ambulatory surgery centers (ASCs) where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country.
IMMY: 7.91 (-0.09)
Imprimis acquires second pharmacy
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:43AM CST
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California
PR Newswire - Tue Dec 02, 7:05AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a stock purchase agreement to acquire South Coast Specialty Compounding, Inc., DBA Park Compounding (Park). The acquisition of Park is expected to close on or about January 1, 2015, subject to the satisfaction of certain customary closing conditions. As part of the transaction, Imprimis also entered into a non-exclusive license agreement with Park. The license agreement allows Park to immediately begin making and dispensing Imprimis' proprietary ophthalmology and urology formulations in the 13 states in which it is currently licensed, including California, Nevada, Oregon, and Hawaii.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals EPS of -$0.27
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:26PM CST
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments
PR Newswire - Wed Nov 12, 3:00PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced financial results for the third quarter ended September 30, 2014, and provided an update on recent business developments.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014
PR Newswire - Thu Nov 06, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, reported that it will release its third quarter 2014 financial results on Wednesday, November 12, 2014. The company will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day to discuss the third quarter 2014 financial results and recent business development activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless(TM) Proprietary Formulations to Ophthalmologists in Puerto Rico
PR Newswire - Tue Nov 04, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a distribution agreement with MD Distributor, Corp. (MDD). Under the agreement, MDD has the rights to market, sell and distribute Imprimis' patent-pending Go Dropless(TM) formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement also covers the Dominican Republic and countries in the Caribbean once regulatory approvals are obtained. MDD represents leading healthcare companies and its experienced sales and marketing professionals are primarily focused in the specialty areas of ophthalmology and dermatology.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation
PR Newswire - Wed Oct 29, 7:31AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700.
IMMY: 7.91 (-0.09)
Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
PR Newswire - Fri Oct 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois. The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible".
IMMY: 7.91 (-0.09)
